Document:

Exhibit
10.23 

 

Amendment

Series
A Loan Agreement

 

 

"Amendment"

 

of

 

 

 

 

 

 

between

 

NLS
Pharmaceutics AG

Alter
Postplatz 2

CH-6370
Stans

"Borrower"

 

 

and

 

 

Magnetic
Rock Investment AG

c/o
Ronald Hafner

Weinbergstrasse
72

CH-8703
Erlenbach ZH

 

 

"Lender"

 

 

(Borrower
and Lender each a ʺPartyʺ

collectively
the ʺPartiesʺ)

 

     

    	Amendment
	2/3

    

 

WHEREAS

 

	A.	The
                                         Borrower is a Swiss stock corporation with its registered office at Alter Postplatz 2,
                                         6370 Stans, Switzerland, and company no. CHE-447.067.36 active in the area of developing
                                         and commercializing the active ingredient Mazindol for the treatment of ADHD.
	 	 

	B.	The
                                         Lender and the Borrower entered into a duly executed series A loan agreement ("Agreement"),
                                         whereas the Lender grants to the Borrower a loan in the amount of CHF 500'000.00 ("Loan
                                         Amount").
	 	 

	C.	The
                                         maturity date for the repayment of the Loan Amount with accrued interest was set at 30 September
                                         2020 ("Maturity Date").

 

NOW,
THEREFORE, the Parties agree as follows:

 

Any
capitalized terms, if not defined otherwise in this Amendment, shall have the meaning as set forth in the Agreement.

 

		1.	Extension
                                         of Maturity Date

 

The
Maturity Date as set forth in section 6 of the Agreement shall be retrospectively extended from 30 September 2020 to 31 December
2020.

 

The
Parties therefore confirm that no default interest as set forth in section 4.2 of the Agreement has accrued so far. In any case,
the Lender waives any claim with regard to default interest.

 

	2.	Governing
                                         law and jurisdiction
	 	 

		2.1.	Governing
                                         Law

 

This
Amendment shall in all respects be governed by and construed in accordance with the substantive laws of Swiss law.

 

		2.2.	Jurisdiction

 

All
disputes arising out of or in connection with this Amendment, including disputes regarding its conclusion, validity, binding effect,
amendment, breach, termination or rescission shall be subject to the exclusive jurisdiction of the ordinary courts of Zurich,
canton of Zurich, Switzerland, venue being Zurich 1.

 

[signature
page to follow]

 

     

    	Amendment
	3/3

    

 

IN
WITNESS WHEREOF, the Parties have signed this Amendment on the date first written above

 

Magnetic
Rock Investment AG

 

	/s/
Ronald Hafner	 	 
	Name:   Ronald Hafner	 	Name:
	Function:   Chairman of the Board	 	Function:
	 	 	 
	 	 	 
	NLS
    Pharmaceutics AG	 	 
	 	 	 
	/s/
Ronald Hafner	 	/s/ Alexander Zwyer
	Name:   Ronald Hafner	 	Name:
    Alexander Zwyer
	Function:   Chairman of the Board	 	Function:  CEOExhibit 10.24

 

 Execution
template

 

 

 

	
        _________________________________________________________

         

        Amendment
        of the

        convertible
        Loan AGREEMENT

        _________________________________________________________

         

        (“Amendment”)

         

        of

         

         

        ___________________

         

        between

         

         

        NLSPharmaCEUTICS
        AG

        as Borrower

         

         

        and

         

         

        [...]

        as Lender

         

         

         

        each a “Party”, together the
        “Parties”

 

 

 

 

Amendment of Convertible Loan Agreement       Confidential 

 

     

     

    

 

WHEREAS the Parties entered
into a convertible loan agreement dated ____________________ (“Convertible Loan Agreement”).

 

WHEREAS Section 4 of the
Convertible Loan Agreement sets forth that the Borrower may at its own and entire discretion repay the loan with accrued
interests, if any, starting December 23 2020 (“Conversion Date Borrower”).

 

WHEREAS the Parties agree in
accordance with Section 10.6 of the Convertible Loan Agreement to amend Section 4 of the Convertible Loan Agreement and to
extend the Conversion Date Borrower for a period of six (6) month until June 23 2021.

 

		1.	Extension of Conversion Date Borrower

 

The Parties hereby agree to extend the
Conversion Date Borrower by six (6) month from December 23 2020 to June 23 2021.

 

		2.	Remaining Provisions

 

Except for the amendments provided herein,
all remaining provisions of the Convertible Loan Agreement shall remain unchanged and binding for the Parties.

This Amendment shall form an integral part
of the Convertible Loan Agreement.

 

		3.	Governing Law and Jurisdiction

 

This Amendment shall be governed by and
construed in accordance with the substantive laws of Switzerland, without reference to principles of conflict of laws or choice
of laws.

 

All disputes arising out of or in connection
with the Amendment, including disputes on its conclusion, binding effect, amendment and termination, shall be resolved by the ordinary
courts of Zurich, canton of Zurich, Switzerland, venue being Zurich 1.

 

 

[signature page to follow]

 

    	Amendment Convertible Loan Agreement	Confidential
	-2-

     

    

 

IN WITNESS WHEREOF, the Parties
acknowledges their understanding and acceptance of the terms of this Agreement and have agreed to sign it on the date first written
above

 

The Borrower

 

NLS Pharmaceutics AG

 

	 	 	 
	Alexander Zwyer	 	Ronald Hafner
	Member of the Board 	 	Chairman of the Board

 

 

The Lender

 

 

 

Name:

 

 

 

	Amendment Convertible Loan Agreement	Confidential	-3-Exhibit 10.25

  

NLS
Pharmaceutics Ltd.

Alter
Postplatz 2

CH-6370
Stans

 

___
October 2020

  

Addendum
Number 3 to Promissory Note (“Addendum”)

 

 

 _________ Schützenstrasse 12, 8702 Zollikon
(the “Lender”), granted to NLS Pharmaceutics Ltd. (formerly NLS-1 Pharma AG), a Swiss stock
corporation with its registered office at Alter Postplatz 2, 6370 Stans, Switzerland, and company no. CHE-447.067.367 (the
“Borrower”), based on the promissory note dated _________ 2019, as amended on _________ 2019 and on
_________ 2020 (the “Promissory Note”) the principal sum of CHF 125,000.00 (the “Principal
Amount”), together with interest at 10.0% p.a. (the “Interest”) thereon accruing on and from the
date of payment until the entire Principal Amount is repaid (the Interest and the Principal Amount hereinafter jointly
referred to as the “Loan”).

 

The
Principle Amount was paid to the Borrower on _________ 2019 (the “Date of Payment”). The full amount of
the Loan, including accrued Interest, is outstanding as of the date of this Addendum.

 

The
following is a statement of the amended terms and conditions of the Promissory Note:

 

	1
                                         – Extension Maturity Date

         
	According
                                         to section 2 of the Promissory Note, the Loan shall be repaid in full on the Maturity
                                         Date and therefore the repayment of the Loan was agreed to take place no later than 30
                                         September 2020.

         

        According
        to section 2 of the Promissory Note, the Lender may unilaterally extend the repayment term and set a new Maturity Date.

         

        The
        Lender hereby extends the Maturity Date of the Loan, replacing the existing maturity date, until 31 December 2020 and,
        thus, the Loan shall be due for repayment no later than 31 December 2020. The Borrower hereby acknowledges and agrees
        with the extension. References to the Maturity Date in the Promissory Note shall be to 31 December 2020.

         

	2
    – Governing Law	This
Addendum shall be governed by and construed in accordance with the substantive laws of Switzerland, without reference to principles
of conflict of laws or choice of laws.

	 	 
	3
    – Jurisdiction	All
disputes arising out of or in connection with this Addendum, including disputes regarding its conclusion, validity, binding effect,
amendment, breach, termination or rescission shall be subject to the exclusive jurisdiction of the ordinary courts of Stans (NW).

 

 

	The Lender	 	The Borrower	 	 
	 	 	NLS Pharmaceutics Ltd

	 
	 	 	 	 	 
	 	 	 	 	 
	Lender

	 	Alexander Zwyer

	 	Ronald Hafner

		 	Chief Executive Officer

	 	Chairman of the Board of DirectorsExhibit
10.26

 

Addendum
Number 3 of the “Up to USD

150,000.00 Credit Facilites Agreement”

 

“Addendum”

 

of

 

___
October 2020

 

between

  

	NLS
    Pharmaceutics Ltd.	 	 
	Alter
    Postplatz	 	 
	6370
    Stans	 	 
	Switzerland	 	“Borrower”
	 	and	 
	Ronald
    Hafner	 	 
	 	 	“Lender
    1”
	Jürgen
    Bauer	 	 
	 	 	“Lender
    2”
	Peter
    Ödman	 	 
	 	 	“Lender
    3”
	Michael
    Stein	 	 
	 	 	“Lender
    4”
	 	 	 
	 	 	(Lender
    1, Lender 2, Lender 3 and Lender 4
	 	 	the  Lenders
    )
	 	 	(Borrower
    and Lenders each a  Party
	 	 	collectively
    the  Parties )

 

regarding

current
situation and outstanding amount

 

     

    	Addendum	2/3

    

 

WHEREAS

 

		A.	The
                                         Borrower is a stock corporation (Aktiengesellschaft) in accordance with Swiss
                                         law with its registered seat and principal place of business at Stans (Company Number
                                         CHE-447.067.367). The Company has a share capital of CHF 139’200.00, divided into
                                         6’960’000 registered shares with a nominal value of CHF 0.02 each, which
                                         have been fully paid in.

 

		B.	The
                                         Lenders and the Borrower (formerly NLS Pharma AG) entered into the “Up to USD 150,000.00
                                         Credit Facilities Agreement” dated 31 August 2015, as amended on 16 September 2019
                                         and on 3 February 2020 (“Agreement”). The Lenders agreed to make available
                                         to the Borrower credit facilities in the aggregate amount of USD 150,000.00 (“Total
                                         Credit Facility Amount”).

 

		C.	The
                                         Lenders granted to the Borrower the Total Credit Facility Amount under the Agreement.

 

		D.	According
                                         to section 6.1 of the Agreement, the loans under Total Credit Facility Amount shall bear
                                         regular interest at the rate of 0% per annum, calculated from (and including) the day
                                         of its drawdown to (and including) the Maturity Date (or the date of its earlier repayment).

 

		E.	According
                                         to section 6.2 of the Agreement, default interest rate of 5% per annum shall apply, in
                                         case the Borrower does not make any payment on the due date as foreseen in the Agreement.

 

		F.	The
                                         maturity date for the repayment of the Total Credit Facility Amount together with the
                                         accrued interest was set at 30 September 2020 (“Maturity Date”).

  

NOW,
THEREFORE, the Parties agree as follows:

 

Any
capitalized terms, if not defined otherwise in this Addendum, shall have the meaning as set forth in the Agreement.

 

		1.	Open
                                         Amount

 

The
Parties hereby confirm that the Total Credit Facility Amount has not been repaid to the Lenders by the Borrower.

 

		2.	Extension
                                         Maturity Date

 

The
Maturity Date as set forth in section 5 of the Agreement shall be extended from 30 September 2020 to 31 December 2020.

 

		3.	Governing
                                         Law and Jurisdiction

 

This
Addendum shall be governed by and construed in accordance with the substantive laws of Switzerland, without reference to principles
of conflict of laws or choice of laws.

 

All
disputes arising out of or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment
and termination, shall be resolved by the ordinary courts in Stans (NW), Switzerland.

 

[Signature
page to follow]

 

     

    	Addendum	3/3

    

  

Borrower 

 

NLS
Pharmaceutics Ltd.

  

	/s/
Ronald Hafner	 	/s/ Alexander Zwyer
	Ronald
    Hafner	 	Alexander
    Zwyer
	Chairman
    of the Board	 	Chief
    Executive Officer
	 	 	 
	 	 	 
	Lenders	 	 
	 	 	 
	/s/ Ronald
    Hafner	 	/s/ Jürgen
    Bauer
	Ronald
    Hafner	 	Jürgen
    Bauer
	 	 	 
	/s/ Peter
    Ödman	 	/s/ Michael
    Stein
	Peter
    Ödman	 	Michael
    Stein

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]